Public Employees Retirement System of Ohio Invests $13.99 Million in United Therapeutics Corporation $UTHR

Public Employees Retirement System of Ohio bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 25,816 shares of the biotechnology company’s stock, valued at approximately $13,988,000. Public Employees Retirement System of Ohio owned 0.06% of United Therapeutics as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Fiduciary Financial Advisors acquired a new position in shares of United Therapeutics during the 2nd quarter valued at $30,000. Entrust Financial LLC purchased a new position in United Therapeutics in the fourth quarter valued at about $31,000. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $48,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $515.46 on Monday. United Therapeutics Corporation has a fifty-two week low of $303.08 and a fifty-two week high of $609.35. The business has a 50 day moving average price of $530.46 and a two-hundred day moving average price of $539.16. The firm has a market cap of $22.11 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $6.41 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the topic of several analyst reports. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $646.00.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at $167,827,875.04. This trade represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 404,575 shares of company stock valued at $216,652,640. Insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.